Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 2/2020

01-04-2020 | Prostate Cancer | Interesting Image

Renal Potassium Excretion Visualized on 82Rubidium PET/CT

Authors: Mads Ryø Jochumsen, Lars Poulsen Tolbod, Michael Borre, Jørgen Frøkiær, Kirsten Bouchelouche, Jens Sörensen

Published in: Nuclear Medicine and Molecular Imaging | Issue 2/2020

Login to get access

Abstract

The positron emission tomography (PET) flow tracer 82Rubidium is a known potassium analogue. During our studies of tumor blood flow in prostate cancer, we found that approximately 10% of the patients had high urinary 82Rubidium activity. In roughly half of these patients, the increased renal rubidium/potassium excretion was either causing hypokalemia or explained by Thiazide treatment. In the other half, there was no obvious explanation or clinical consequence of the renal rubidium/potassium excretion. This is the first time enhanced renal potassium excretion is visualized on 82Rubidium PET/CT.
Literature
1.
Chatal JF, Rouzet F, Haddad F, Bourdeau C, Mathieu C, Le Guludec D. Story of Rubidium-82 and advantages for myocardial perfusion PET imaging. Front Med (Lausanne). 2015;2:65.
2.
Lu Y. FDG and (82)Rb PET/MRI features of brain metastasis of breast cancer. Clin Nucl Med. 2015;40:494–5.CrossRef
3.
Mirpour S, Khandani AH. Extracardiac abnormalities on rubidium-82 cardiac positron emission tomography/computed tomography. Nucl Med Commun. 2011;32:260–4.CrossRef
4.
Murthy VL, Brown RK, Corbett JR. Metastatic renal cell carcinoma avid for 82Rb but not 18F-FDG. Clin Nucl Med. 2014;39:908–9.CrossRef
5.
Neumann DR, Basile KE, Bravo EL, Chen EQ, Go RT. Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. J Comput Assist Tomogr. 1996;20:312–6.CrossRef
6.
Jochumsen MR, Tolbod LP, Pedersen BG, Nielsen MM, Hoyer S, Frokiaer J, et al. Quantitative tumor perfusion imaging with (82)Rb PET/CT in prostate cancer: analytic and clinical validation. J Nucl Med. 2019;60:1059–65.CrossRef
7.
Jochumsen MR, Bouchelouche K, Nielsen KB, Frokiaer J, Borre M, Sorensen J, et al. Repeatability of tumor blood flow quantification with (82)Rubidium PET/CT in prostate cancer - a test-retest study. EJNMMI Res. 2019;9:58.CrossRef
8.
Kunin AS, Dearborn EH, Burrows BA, Relman AS. Comparison of renal excretion of rubidium and potassium. Am J Phys. 1959;197:1297–302.CrossRef
9.
Kilpatrick R, Renschler HE, Munro DS, Wilson GM. A comparison of the distribution of 42K and 86Rb in rabbit and man. J Physiol. 1956;133:194–201.CrossRef
10.
Beck FX, Giebisch G, Thurau K. Effect of K depletion on renal K and Rb excretion: evidence for activation of K reabsorption. Kidney Int. 1992;42:272–8.CrossRef
11.
Parihar AS, Coghlan MJ, Gopalakrishnan M, Shieh CC. Effects of intermediate-conductance Ca2+−activated K+ channel modulators on human prostate cancer cell proliferation. Eur J Pharmacol. 2003;471:157–64.CrossRef
12.
Tahari AK, Bravo PE, Rahmim A, Bengel FM, Szabo Z. Initial human experience with Rubidium-82 renal PET/CT imaging. J Med Imaging Radiat Oncol. 2014;58:25–31.CrossRef
Metadata
Title
Renal Potassium Excretion Visualized on 82Rubidium PET/CT
Authors
Mads Ryø Jochumsen
Lars Poulsen Tolbod
Michael Borre
Jørgen Frøkiær
Kirsten Bouchelouche
Jens Sörensen
Publication date
01-04-2020
Publisher
Springer Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 2/2020
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-020-00637-8

Other articles of this Issue 2/2020

Nuclear Medicine and Molecular Imaging 2/2020 Go to the issue

Review

Preclinical Voxel-Based Dosimetry in Theranostics: a Review

Original Article

First In-Human Medical Imaging with a PASylated 89Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer

Original Article

Radioactivity Reduction of 2-Deoxy-2-[18F] Fluoro-D-Glucose by Milk and Ursodeoxycholic Acid in Preclinical Study

Review

From Theranostics to Immunotheranostics: the Concept

Perspective

Sleep and Neuroimaging

Review

New Frontiers in Molecular Imaging with Superparamagnetic Iron Oxide Nanoparticles (SPIONs): Efficacy, Toxicity, and Future Applications